B. Riley raised the firm’s price target on Eton Pharmaceuticals (ETON) to $24 from $21 and keeps a Buy rating on the shares. The pullback following Eton’s quarterly earnings report is likely due to $80M run-rate guidance vs. the $100M buy-side number, though this overlooks the conservative nature of the guidance that excludes the ET-400 contribution in FY25, providing a nice entry opportunity, the analyst tells investors in a research note. The firm sees a three-step path to $100M/$300M in annual revenue run-rate by 1Q26/1Q28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals price target raised to $26 from $23 at Craig-Hallum
- Promising Growth Prospects and Strategic Initiatives Justify Buy Rating for Eton Pharmaceuticals
- Eton Pharmaceuticals Reports Record Q4 Revenue Growth
- Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions
- Eton Pharmaceuticals to Host Virtual Investor Day